A Phase 2 interventional study of AdMSC and Placebo in Systemic Sclerosis, sponsored by University Hospital, Toulouse. Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University Hospital, Toulouse · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 132 studies in Scleroderma, Systemic with a site in France — 44 open to participants now, 48 under way, 7 of them phase 3. Scleroderma, Systemic · France.
Among the 132 studies in Scleroderma, Systemic with a site in France, this one is the 62nd largest by planned enrollment of the 81 interventional ones that give a count, is one of 8 that started in 2020, is one of 21 in phase 2, reaches primary completion later than 16 of the 47 other live ones, and was the 71st registered.
614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.
Browse Scleroderma, Systemic studies →44 of the 132 studies in Scleroderma, Systemic with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18–85 · Healthy volunteers
AstraZeneca · Sites in France, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in France, United States, Argentina and 42 more countries
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18–64
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 147 Scleroderma, Systemic studies recruiting now, 85 (58%) set no upper age limit and 49 (33%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
132 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 28 · Phase 3 15
First in 2001; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 37 across 450 interventional studies indexed under Scleroderma, Systemic.
Median enrollment 75 across the 81 interventional studies, 150 across the 50 observational. Of the 71 that completed or were terminated, 8 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 132 have an industry lead sponsor. The 10 most frequent:
University Hospital, Toulouse is the lead sponsor of 809 studies on the registry; 211 are open to participants now.
University Hospital, Toulouse has 2 studies filed under Scleroderma, Systemic — fewer than ten, so there is no comparison to draw.
7 of the studies in Scleroderma, Systemic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT06655155argenxA Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis | 2027-03 |
| NCT04356755University Hospital, ToulouseSubcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma. | 2027-03 |
| NCT07888842Assistance Publique - Hôpitaux de ParisA Clinical Study on Systemic Sclerosis and the Validation of French-language Questionnaires Assessing Disability, Quality of Life, and Disease Status. | 2027-05 |
| NCT07543679Centre Hospitalier Universitaire de Saint EtienneObjective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis | 2027-05-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 132 studies in Scleroderma, Systemic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ischemic digital ulcers (DUs) are a frequent complication in systemic sclerosis with a major impact on hand function and quality of life. Digital injection of cultured adipose-derived stromal cell (AdMSC) constitutes a promising approach to treat scleroderma-induced refractory ischemic DUs where no alternative therapy is validated. The aim of this phase 2 study is to compare efficacy and safety of digital injection of AdMSC versus placebo for healing refractory active ischemic digital ulcers in patients with systemic sclerosis.
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by an autoimmune-mediated microangiopathy and progressive fibrosis. Ischemic digital ulcers (DUs) are frequent in the disease course. DUs are an expression of the severity of the microangiopathy. DUs lead to pain, infection, gangrene, autoamputation, impaired hand use and impaired quality of life. The management of DUs is often based on optimal wound care to promote healing and and repeated hospitalizations to perform onerous prostacyclin infusions to reduce pain and accelerate healing. With optimal standard of care, only 60% of DUs are healed after 3 months and 46.2% experiences recurrence during that time among them 11.2% experiences a chronic evolution. No drug has demonstrated a positive effect on refractory DUs healing. The rational underlying the use of cultured adipose-derived stromal cell (AdMSC) in this indication is based on the finding of AdMSC, in vitro and in vivo, angiogenic and anti-inflammatory potential in other ischemic pathologies, with an excellent safety profile. The pilot phase of the ACellDREAM trial demonstrated the feasibility and safety of AdMSC transplantation in patients with non- revascularizable critical limb ischemia and showed improvement in ulcer evolution and wound healing. The EFS-O culture procedure safety is validated and is already in use in ongoing French and European clinical trials. Two pilot studies showed the safety of adipose tissue grafting for scleroderma-Induced DU. The SCLERADEC pilot study outlines the safety, in 12 SSc patients, of the digital injection of adipose- derived stromal vascular fraction, which is a heterogeneous population of cells including only 36% of uncultured AdMSC. An improvement in hand disability, quality of life and DUs was observed, the phase II is ongoing. The hypothesis of the study is that digital injection of AdMSC could be efficacious for scleroderma-induced refractory ischemic DUs healing by digital vascular regeneration in a clinical situation where no alternative therapy is validated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The DU at " inclusion visit " must show all the following characteristics:
Exclusion Criteria:
Relative to each DU:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous injections of cultured adipose-derived stroma/stem cells to heal refractory ischemic digital ulcers in patients with scleroderma
Drug: AdMSC
Subcutaneous injections of placebo comparator to heal refractory ischemic digital ulcers in patients with scleroderma
Drug: Placebo
At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks
At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
Proportion of refractory active ischemic digital ulcers healed (complete or partial)
Partial healing is defined as \> 50% reduction of the DU area or \> 50% re epidermisation of the DU.
Time frame: 16 weeks
Composite endpoint combining healing (complete or partial) without recurrence and without local or general complications
Partial healing is defined as \> 50% reduction of the DU area or \> 50% re epidermisation of the DU. Local complications resulting from DU worsening: * Critical ischemic crisis necessitating hospitalization, * Gangrene, (auto) amputation, * Failure of conservative management: Surgical and chemical sympathectomy, vascular reconstructions, or any unplanned surgery in the management of hand SSc manifestation(s), * Use of parenteral prostanoids after treatment injection, * Requiring class II, III or IV narcotics or increase in existing dose of \> 50 % as compared to baseline, * Initiation of systemic antibiotics for the treatment of infection attributed to digital ulceration. General complications will be assessed by: * Clinical examination * Patient reported-outcomes * Laboratory assessments
Time frame: 16 weeks
Percentage of participants with Digital Ulcer complete healing
Number of complete ulcer Healing. Complete healing is defined as 100% re-epidermisation.
Time frame: 16 weeks
Percentage of participants with Digital Ulcer partial healing
Number of partial ulcer Healing. Partial healing is defined as \> 50% reduction of the DU area or \> 50% re epidermisation of the DU.
Time frame: 16 weeks
Percentage of participants with wound surface reduction <50%
the wound surface reduction is defined by analysis photography
Time frame: 16 weeks
Percentage of participants with new Digital Ulcer
Number of patients who do not develop any new DU.
Time frame: 16 weeks
Percentage of participants with Digital Ulcer complication
A complication is an infection, gangrene, amputation or a DU requiring IV prostanoids.
Time frame: 16 weeks
Change from Baseline in Pain Scores
Evaluation of pain on a Visual Analog Scale. The visual scale measures the intensity of pain on a scale ranging from 0 (no pain) to 10 (maximum pain).
Time frame: 16 weeks
Change from Baseline in severity of Raynaud's phenomenon
Change in severity of Raynaud's phenomenon on a Visual Analog Scale. The visual scale is in a form of plastic ruler and measures the severity of Raynaud's phenomenon on a scale ranging from 0 (no pain) to 100 (maximum pain).
Time frame: 16 weeks
Change from Baseline in Digital ischaemia
Change in digital ischaemia of the treated fingers on Digital arterial pressure.
Time frame: 16 weeks
Change from Baseline in cutaneous ischaemia
Change in cutaneous ischaemia of the treated fingers on transcutaneous oxygen pressure (TcPO2).
Time frame: 16 weeks
Change from Baseline in Digital microvascular organisation
Change in digital microvascular organisation of the treated fingers on nailfold capillaroscopy.
Time frame: 16 weeks
Change from Baseline in hand functional disability
Evaluation of hand functional disability by the Cochin Hand Function Scale.
Time frame: 16 weeks
Change from Baseline in quality of life in systemic sclerosis
Evaluation of quality of life in systemic sclerosis by scleroderma health assesment (SHAQ).
Time frame: 16 weeks
Change from Baseline in quality of life
Evaluation of quality of life by the SF36.
Time frame: 16 weeks
Change from Baseline in health status
Evaluation of health status by the EQ5D.
Time frame: 16 weeks
Vascular biomarkers
Endothelin-1, Endostatin, Endogline, Angiotensin I and II, Tie 1 and 2, V-EGF, sICAM-1, sVCAM, E-selectin, CXCL4 plus anti-AT1R, anti-ETAR, anti Annexin V will be measured out in blood samples by Luminex
Time frame: 16 weeks
Started Sep 2020 (actual). Primary completion is estimated for Mar 2027, 78 months after the start.
Of 48 phase 2 interventional studies under Scleroderma, Systemic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 83. This study's planned 78 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →